What's new

Human medicines European public assessment report (EPAR): Siiltibcy, Mycobacterium tuberculosis derived antigens (rdESAT-6 / rCFP-10), Date of authorisation: 13/01/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Siiltibcy, Mycobacterium tuberculosis derived antigens (rdESAT-6 / rCFP-10), Date of authorisation: 13/01/2025, Revision: 1, Status: Authorised

Mar 24, 2025 - 16:44
 0
Human medicines European public assessment report (EPAR): Siiltibcy, Mycobacterium tuberculosis derived antigens (rdESAT-6 / rCFP-10), Date of authorisation: 13/01/2025, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Siiltibcy, Mycobacterium tuberculosis derived antigens (rdESAT-6 / rCFP-10), Date of authorisation: 13/01/2025, Revision: 1, Status: Authorised
Read More

Tags:

Previous Article

Gavi terminates COVID vaccine deal with Clover, demands $224M repayment

Next Article

Opinion/decision on a Paediatric investigation plan (PIP): Blincyto, blinatumoma...

Related Posts

Human medicines European public assessment report (EPAR): Inrebic, fedratinib, Date of authorisation: 08/02/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 5, 2025  0

Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 11, 2025  0

Orphan designation: Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene Treatment of mucopolysaccharidosis type II (Hunter's syndrome), 10/08/2015 Withdrawn

Orphan designation: Adeno-associated viral vector serot...

Feb 20, 2025  0